Product image of Orylmyte (Dermatophagoides Pteronyssinus, Dermatophagoides Farinae) supplied by GNH India

Orylmyte

Active Ingredient:
Dermatophagoides Pteronyssinus, Dermatophagoides Farinae
Origin:
EU

Orylmyte (Dermatophagoides Pteronyssinus, Dermatophagoides Farinae)

Dermatophagoides pteronyssinus and Dermatophagoides farinae, the active ingredients in Orylmyte, are a standardized allergen extract presented as a 1:100 w/v extract for subcutaneous injection use. They are employed in allergen immunotherapy to reduce symptoms of allergic rhinitis and asthma caused by house dust mite sensitivity.

GNH India supplies Orylmyte as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Stallergenes

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Orylmyte is used in allergen immunotherapy targeting the house dust mite allergy pathway.

  • Allergic rhinitis (dust mite): reduces nasal congestion, sneezing and itching.
  • Allergic asthma (dust mite): decreases bronchial hyper‑responsiveness and inhaler reliance.
  • Persistent allergic conjunctivitis (dust mite): alleviates eye itching and tearing.

How It Works

  • Orylmyte contains purified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae proteins that are administered subcutaneously to induce immune tolerance. Repeated exposure shifts the immune response from a Th2‑dominant, IgE‑mediated profile toward a regulatory T‑cell and IgG4 response, thereby diminishing allergic inflammation upon natural exposure to dust‑mite allergens.

Side Effects

Adverse reactions may occur following subcutaneous administration of Orylmyte.

Common Side Effects

  • Local redness at injection site: mild erythema lasting a few hours.
  • Swelling at injection site: transient edema.
  • Itching at injection site: brief pruritus.
  • Low‑grade fever: temporary temperature rise.
  • Headache: mild discomfort.
  • Fatigue: short‑term tiredness.

Serious or Rare Side Effects

  • Anaphylaxis: rapid onset of systemic allergic reaction.
  • Severe bronchospasm: acute airway narrowing.
  • Angio‑edema: swelling of lips, tongue or face.
  • Serum sickness‑like reaction: joint pain and rash.
  • Persistent urticaria: lasting hives beyond 24 hours.
  • Neurological symptoms: rare dizziness or paresthesia.

Precautions & Warnings

Prior to initiating therapy with Orylmyte, several safety considerations should be observed.

  • Contraindication: avoid use in patients with a history of severe anaphylaxis to dust‑mite extracts.
  • Monitoring: observe patients for at least 30 minutes after each injection for systemic reactions.
  • Pregnancy: use only if clearly needed; limited data are available.
  • Breastfeeding: consider potential exposure to infant; weigh benefits versus risks.
  • Comorbid asthma: ensure asthma is well‑controlled before starting immunotherapy.
  • Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Avoid Interactions

Orylmyte may interact with other agents that affect immune response or increase the risk of allergic reactions.

Major Interactions (Avoid)

  • Beta‑blockers: may mask anaphylaxis symptoms and hinder treatment.
  • ACE inhibitors: can exacerbate angio‑edema risk.

Moderate Interactions (Monitor Closely)

  • Antihistamines: may reduce local skin test reactivity, requiring timing adjustments.
  • Immunosuppressants: could diminish the efficacy of immunotherapy.
  • Other allergen extracts: concurrent administration may increase systemic reaction risk.
  • Live vaccines: schedule immunotherapy away from vaccine administration.

Frequently Asked Questions

Orylmyte is an allergen extract containing Dermatophagoides pteronyssinus and Dermatophagoides farinae proteins. It is used in subcutaneous immunotherapy to treat allergic rhinitis, allergic asthma, and related dust‑mite‑induced allergic conditions by building long‑term tolerance to the allergens.

The Dermatophagoides proteins in Orylmyte stimulate the immune system to shift from an IgE‑driven allergic response toward a regulatory and IgG4‑dominant response. This immune modulation reduces the severity of symptoms when the patient is later exposed to natural dust‑mite allergens.

The dosing regimen for Orylmyte is individualized. The prescribing clinician determines the concentration, volume, and schedule of injections based on the patient’s sensitivity, age, and clinical response.

Safety data for Orylmyte in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk, and the decision must be made by the treating physician in consultation with the patient.

To order Orylmyte, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Orylmyte contains a standardized blend of both Dermatophagoides pteronyssinus and Dermatophagoides farinae extracts, offering broader coverage than single‑species preparations. Its formulation follows EU standards for potency and purity, which may provide consistent clinical outcomes compared with non‑standardized extracts.

Orylmyte should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperature fluctuations to maintain potency.

Orylmyte is given by subcutaneous injection, typically in a healthcare setting. The injection is performed by a trained professional, and patients are observed for a period after each dose to monitor for any systemic reactions.

The most serious risks include systemic anaphylaxis, severe bronchospasm, and angio‑edema. Immediate medical intervention is required if any of these reactions occur, and patients should be monitored closely after each injection.

Individuals with a known severe allergic reaction to dust‑mite extracts, uncontrolled asthma, or those taking beta‑blockers without medical supervision should avoid Orylmyte. The product is also contraindicated in patients with a history of anaphylaxis to any component of the formulation.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Dermatophagoides Pteronyssinus, Dermatophagoides Farinae

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT